TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Use of face coverings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean change in unmedicated Intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eyes achieving a 20% or greater reduction in unmedicated Intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in symptom control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant placement accuracy at the implant platform level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Implant placement accuracy at the implant apex level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Implant placement accuracy at an angular level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Implant placement accuracy at the vertical plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Perceived Competence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 2-hour post-load glucose (2hPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation of measured concentrations of orally used DMDs with the clinical condition of patients with MS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objectification of adherence to treatment in individual DMDs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The percentage of patients with DMDs in whom therapeutic monitoring is used
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Musculoskeletal Tumor Society Score (MSTS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life Questionnaire C-30 (QLQ-C30)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Participation and Autonomy Questionnaire (IPAQ)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Multiple Sclerosis Self-Efficacy Control scale (MSSE-C)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy assessed by oral ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Learning accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic use
Endpoint domain: Adverse events/effects
Primary endpoint: AUCplt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Nutritional status, as assessed by Body Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Muscle Mass Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: QTc interval effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of emergence after rigid bronchoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in SAD-related symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success of procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular Ejection Fraction (LVEF) <50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum vitamin B12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum vitamin D3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Preliminary Safety and Tolerability: incidence and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Trigeminal component
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Positive And Negative Syndrome Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum persistent organic pollutants (POPs) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Six minute walk test time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy/therapeutic response of HPV vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune profile comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Grades 3-5 Treatment-Related Immune-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Category
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent change in 28-day seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: cutaneous vascular conductance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: brachial artery diameter and blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Sera LOX-1 protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy LOX-1 protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PrEP uptake by self-report
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PrEP uptake by pharmacy records
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PrEP adherence by self-report
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PrEP adherence by dried blood spot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ballistic acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in excitability of cortical and corticospinal physiology and interhemispheric connections (TMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in excitability of spinal physiology (F-wave)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Uptake of Preventative Sexual Health Services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: IM regression rate one year after H. pylori eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Margins of Stability (MoS) in anterior-posterior direction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of No-Reflow phenomena
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participants' experience of the diagnostic circumstances and care pathway
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Incidence of disturbance in ophthalmology training programs
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Whole body Lean body Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prognostic value of MRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Solicited Injection Site Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Achilles Tendon Rupture Score (ATRS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of interrupting MTCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HBV DNA load in pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ALT levels in pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBeAg conversion rate in pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Academic Skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: measure of eye movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl Meyer Assessment of sensorimotor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl Meyer Assessment of sensorimotor function (Short Form)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the multimodal monitoring approach
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Latino MSM Referral for Biomedical HIV Prevention/Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Subjective perceived limitations in ambulation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Use of assigned disposal method
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: self-reported abstinence in the past 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biochemical validated tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: difference of the feasibility and acceptability score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Transition Readiness Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of unaddressed positive margin
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Concentration of JNJ-77242113
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypotension during anesthetic induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psychological well-being at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Burnout at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of adolescent emotional problems (RCADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of adolescent emotional problems (CBCL internalizing)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of adolescent emotional problems (YSR internalizing)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of adolescent behavior problems (CBCL rule-breaking and aggressive behavior)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of adolescent behavior problems (YSR rule-breaking and aggressive behavior)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of MARD (Mean Absolute Relative Difference)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VA improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bone loss at lumbar site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphoscintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indocyanine green (ICG) lymphography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DXA body composition analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organ Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence of all Grade 3 unsolicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Blood biomarkers/inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants with Adverse Events Reported During Safety Evaluations
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Plasma Concentration (Cmax) of ABBV-722
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Tmax) of ABBV-722
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV detection test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from aortic growth requiring secondary reintervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Relaxin measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: First Responder Aphasia Training Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: First Responder Strategies for Aphasia
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: First Responder Confidence in Communication Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in 60-m sprint test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 100-m sprint test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gait parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who complete 12 weeks of therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change rate of glabellar line at maximum frown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in reward-specific dopamine synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: composite response rate for abdominal pain and stool consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fraction of bronchoscopic advancements with unobstructed view of vocal cords
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Preload responsiveness detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Kujala Patellofemoral Scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time up and go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Respiratory Poligraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: brain health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: metabolic function (TEE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 6-meter walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital admission related to chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: AUC0-tlast of midazolam and its hydroxylmetabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of midazolam and its hydroxylmetabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of midazolam and its hydroxylmetabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants that have negative urine culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of participants with incident symptomatic UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Wong-Baker Facial Expression Rating Scale (WB-FRAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in average Plasma Phe Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Physical activity measured by step counts and intensity minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical function (30 second chair stand test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Health Related Quality of Life (EQ5D-5L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants with Contrast-induced nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Autophagic capacity of BPAN cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of target wound related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients undergoing coronary angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Postoperative Nausea and Vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical performance of GALAXY FIXATION™ System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of hypotension symptom events
Endpoint domain: Adverse events/effects
Primary endpoint: Time spent on documentation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of the jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression, Anxiety, Stress scale (DASS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: McGill Pain Questionnaire Short-form
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Functional Assessment of Chronic Illness Therapy - Spiritual Well-being Scale (FACIT-Sp)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of semaglutide
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of semaglutide
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Performance (Efficacy) Endpoint
Endpoint domain: Physiological/clinical
Primary endpoint: Frequency of early asthmatic response (EAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Achieved checklist points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MoCA (Montreal Cognitive Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Wolf Motor Functional Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximal Hand and Pinch Grip Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety in Healthy Volunteers
Endpoint domain: Adverse events/effects
Primary endpoint: Safety in Hereditary Angioedema
Endpoint domain: Adverse events/effects
Primary endpoint: Mean duration of bedridden days over six months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cardiac uptake and release of metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long-term safety of the NVDX3 implant
Endpoint domain: Adverse events/effects
Primary endpoint: modified Rankin Scale score (mRS) ≤ 1 at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximal Observed Concentration (Cmax) of Magnesium in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Observed Concentration (Cmax) of Pyridoxine in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Amount of Unchanged Drug Excreted into the Urine From Time Zero to the Time Point 24 hours (Ae0-24) of Magnesium in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of HCV therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diphtheria, pertussis, and tetanus first dose (DPT1) coverage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diphtheria, pertussis, and tetanus first dose (DPT3) coverage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dropout rate from DPT1 to DPT3
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concentration of carbon monoxide on breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of participants with post-partum depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean depression severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SARS-CoV-2 anti-spike immunoglobulins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: average exposure to regulated pollutants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of FMT
Endpoint domain: Adverse events/effects
Primary endpoint: Intraoperative acquired pressure injury
Endpoint domain: Adverse events/effects